New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that com...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2019-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2384 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849408499472138240 |
|---|---|
| author | N. V. Ilyin K. I. Ivanov T. V. Martynyuk |
| author_facet | N. V. Ilyin K. I. Ivanov T. V. Martynyuk |
| author_sort | N. V. Ilyin |
| collection | DOAJ |
| description | Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that combination therapy with PAH-specific medications can significantly inhibit the development of the disease. Therefore, in modern guidelines, combination therapy is considered as a treatment standard for a significant proportion of patients with PAH. This publication presents a modern view of the selexipag practical using in early combination therapy in patients with PAH. |
| format | Article |
| id | doaj-art-4b8ea3bbdd664576aa8701857600434b |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2019-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-4b8ea3bbdd664576aa8701857600434b2025-08-20T03:35:46Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252019-12-01186808710.15829/1728-8800-2019-6-80-872006New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipagN. V. Ilyin0K. I. Ivanov1T. V. Martynyuk2Republican Hospital № 1 — National Center of MedicineRepublican Hospital № 1 — National Center of MedicineNational Medical Research Center of CardiologyPulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that combination therapy with PAH-specific medications can significantly inhibit the development of the disease. Therefore, in modern guidelines, combination therapy is considered as a treatment standard for a significant proportion of patients with PAH. This publication presents a modern view of the selexipag practical using in early combination therapy in patients with PAH.https://cardiovascular.elpub.ru/jour/article/view/2384selexipagspecific therapypulmonary arterial hyperten¬sioncombination therapy |
| spellingShingle | N. V. Ilyin K. I. Ivanov T. V. Martynyuk New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag Кардиоваскулярная терапия и профилактика selexipag specific therapy pulmonary arterial hyperten¬sion combination therapy |
| title | New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag |
| title_full | New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag |
| title_fullStr | New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag |
| title_full_unstemmed | New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag |
| title_short | New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag |
| title_sort | new treatment options for pulmonary arterial hypertension the first selective ip receptor agonist selexipag |
| topic | selexipag specific therapy pulmonary arterial hyperten¬sion combination therapy |
| url | https://cardiovascular.elpub.ru/jour/article/view/2384 |
| work_keys_str_mv | AT nvilyin newtreatmentoptionsforpulmonaryarterialhypertensionthefirstselectiveipreceptoragonistselexipag AT kiivanov newtreatmentoptionsforpulmonaryarterialhypertensionthefirstselectiveipreceptoragonistselexipag AT tvmartynyuk newtreatmentoptionsforpulmonaryarterialhypertensionthefirstselectiveipreceptoragonistselexipag |